Penn Alzheimer's Disease Research Center (ADRC)

宾夕法尼亚阿尔茨海默病研究中心 (ADRC)

• 批准号: 10663864
• 负责人: DAVID A WOLK
• 金额: $ 309.98万
• 依托单位: UNIVERSITY OF PENNSYLVANIA
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-08-15 至 2026-06-30
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10663864
• 关键词: Achievement; Address; African American population; Alzheimer' s Disease; Alzheimer' s Disease Core Center; Alzheimer' s disease related dementia; Alzheimer' s disease risk; Autopsy; Biocompatible Materials; Bioinformatics; Biological Aging; Biological Markers; Caregivers; Caring; Cerebrovascular Disorders; Clinical; Clinical Data; Cognitive; Collaborations; Communities; Data; Databases; Dedications; Degenerative Disorder; Dementia; Development; Disease; Education; Elderly; Environment; Frontotemporal Dementia; Funding; Genetic; Genomics; Goals; Heterogeneity; Histology; Image; Impairment; Infrastructure; Institution; International; Intervention; Late Onset Alzheimer Disease; Lewy Body Disease; Link; Measures; Methodology; Methods; Mission; Modeling; Molecular Biology; National Institute on Aging; Nerve Degeneration; Neurodegenerative Disorders; Pathologic; Pathology; Patients; Pennsylvania; Personal Satisfaction; Phenotype; Plasma; Prevention; Process; Prognosis; Recording of previous events; Research; Research Personnel; Research Support; Risk; Techniques; Training; Training Programs; Underrepresented Minority; Universities; Validation; Vascular Diseases; biomarker development; cognitive testing; cohort; comorbidity; data management; data sharing; diagnostic biomarker; diagnostic strategy; digital; disease heterogeneity; education research; effective therapy; empowerment; ethical, legal, and social implication; medical schools; molecular pathology; neuroimaging; neuroimaging marker; neuropathology; next generation; normal aging; novel; outreach; precision medicine; programs; racial diversity; recruit; social health determinants; sociodemographics

Penn ADRC Overall Project Summary The mission of the University of Pennsylvania’s Alzheimer’s Disease Research Center (Penn ADRC) is to increase research and education on Alzheimer’s disease (AD) and its links to related dementias (ADRD) with the goal of identifying the causes of and cures for AD/ADRD. To do so, the Penn ADRC will address one of the fundamental barriers to effective treatment or prevention, which is the significant phenotypic, pathological, and sociodemographic heterogeneity of AD. We will embrace and seek to characterize and understand this heterogeneity to ultimately achieve a precision medicine approach leading to targeted interventions that will facilitate realization of the National Alzheimer’s Project Act’s (NAPA) ambitious goal of effective prevention or treatment by 2025. Indeed, the Penn ADRC is constructed to directly contribute to a number of the milestones of NAPA necessary to achieve this goal. Emerging from the 30-year history of the Penn Alzheimer’s Disease Core Center (ADCC), the Penn ADRC benefits from a rich scientific milieu in which there is significant integration and collaboration across Penn’s neurodegenerative disease centers. This construction is critical to the understanding of AD heterogeneity which is driven, in part, by overlapping pathologies and mechanisms, such that cross-degenerative disease studies are of increasing importance in capturing the full spectrum of disease. This environment has led to a history of transformative research that has influenced understanding of disease definition and mechanisms, diagnostic approaches and biomarker development, statistical and bioinformatics methodology, and ethical, social and legal perspectives of those suffering from this condition and their care partners. It has also created an intellectual, cultural, and physical setting dedicated to training the next generation of investigators and clinicians, as well as partnering and educating the community. To achieve our mission, the Penn ADRC will bring together eight cores (Administrative; Biomarker; Clinical; Data Management and Statistical; Genomics; Neuroimaging; Neuropathology; Outreach, Recruitment, and Engagement) and the Research Education Component (REC). These highly integrated cores will support development of a phenotypically, pathologically, and ethno-racially diverse cohort which will be deeply characterized through cognitive assessments, measures of social determinants of health, genetics, biofluid and neuroimaging biomarkers, and autopsy. All these data will be stored within the Integrated Neurodegenerative Disease Database (INDD), which is linked to the other neurodegenerative centers at Penn and will contribute to our understanding of the upstream factors and processes that lead to AD heterogeneity and its downstream manifestations. Further, the ADRC supports robust sharing of these data and participation in larger NIA and national programs. The REC leverages these cores and their research programs for training new investigators. Together, the Penn ADRC will advance our ultimate mission to reduce the tremendous burden of AD.

宾夕法尼亚州 ADRC 总体项目摘要 宾夕法尼亚大学阿尔茨海默病研究中心 (Penn ADRC) 的使命是 加强对阿尔茨海默病 (AD) 及其与相关痴呆 (ADRD) 的联系的研究和教育 确定 AD/ADRD 的原因和治疗方法的目标是，宾夕法尼亚大学 ADRC 将解决其中一项问题。 有效治疗或预防的基础是显着的表型障碍、病理学和 我们将拥抱并努力描述和理解 AD 的社会人口异质性。 异质性最终实现精准医学方法，从而产生有针对性的干预措施 促进实现国家阿尔茨海默病项目法案 (NAPA) 有效预防或 到 2025 年实现治疗。事实上，宾夕法尼亚大学 ADRC 的建立是为了直接为许多里程碑做出贡献 国家适应行动方案 (NAPA) 是实现这一目标所必需的。 宾夕法尼亚州 ADRC 源于宾夕法尼亚州阿尔茨海默病核心中心 (ADCC) 30 年的历史 受益于丰富的科学环境，宾夕法尼亚大学之间存在着重要的整合和合作 神经退行性疾病中心的构建对于理解 AD 异质性至关重要。 这在一定程度上是由重叠的病理和机制驱动的，例如交叉退行性疾病 研究在捕获全谱疾病方面变得越来越重要。 影响对疾病定义和机制的理解的变革性研究的历史， 诊断方法和生物标志物开发、统计和生物信息学方法以及伦理， 它还创造了患有这种疾病的人及其护理伙伴的社会和法律观点。 致力于培养下一代研究人员和研究人员的智力、文化和物质环境 福尔曼，以及与社区合作和教育。 为了实现我们的使命，宾夕法尼亚州 ADRC 将汇集八个核心（行政、生物标志物、临床、和）。 数据管理和统计；神经影像学； 参与）和研究教育组件（REC）这些高度集成的核心将提供支持。 一个表型、病理学和民族种族多样化群体的发展，这将是深刻的 通过认知评估、健康社会决定因素的测量、遗传学、生物体液和 神经影像生物标志物和尸检所有这些数据都将存储在综合神经退行性疾病中。 疾病数据库（INDD），与宾夕法尼亚大学的其他神经退行性中心相关联，并将做出贡献 加深我们对导致AD异质性的上游因素和过程及其下游的认识 此外，ADRC 支持这些数据的强有力共享以及更大的 NIA 和参与。 REC 利用这些核心及其研究项目来培训新的研究人员。 宾大 ADRC 将共同推进我们的最终使命，减轻 AD 的巨大负担。

项目成果

John Q. Trojanowski: neuropathology icon.

John Q. Trojanowski：神经病理学偶像。

• 发表时间: 2022-04
• 影响因子: 12.7
• 作者: Lee; Edward B
• 通讯作者: Edward B

Patients asking about APOE gene test results? Here's what to tell them.

患者询问APOE基因检测结果？

• 发表时间: 2022-05
• 作者: Stites, Shana D;Vogt, Nicholas M;Blacker, Deborah;Rumbaugh, Malia;Parker, Monica W;Advisory Group on Risk Evidence Education for Dementia (AGREED)
• 通讯作者: Advisory Group on Risk Evidence Education for Dementia (AGREED)

Isoform-specific patterns of tau burden and neuronal degeneration in MAPT-associated frontotemporal lobar degeneration.

MAPT 相关额颞叶变性中 tau 负载和神经元变性的异构体特异性模式。

• 发表时间: 2022-12
• 影响因子: 12.7
• 作者: Giannini, Lucia A A;Ohm, Daniel T;Rozemuller, Annemieke J M;Dratch, Laynie;Suh, EunRan;van Deerlin, Vivianna M;Trojanowski, John Q;Lee, Edward B;van Swieten, John C;Grossman, Murray;Seelaar, Harro;Irwin, David J;Netherlands Brain Bank
• 通讯作者: Netherlands Brain Bank

Supported decision making: Facilitating the self-determination of persons living with Alzheimer's and related diseases.

支持决策：促进阿尔茨海默病及相关疾病患者的自我决定。

• 发表时间: 2023-11
• 影响因子: 6.3
• 作者: Largent, Emily A;Peterson, Andrew;Karlawish, Jason
• 通讯作者: Karlawish, Jason

Validating virtual administration of neuropsychological testing in Parkinson disease: a pilot study.

验证帕金森病神经心理学测试的虚拟管理：一项试点研究。

• 发表时间: 2023-09-27
• 影响因子: 4.6
• 作者: Gallagher, Julia;Mamikonyan, Eugenia;Xie, Sharon X;Tran, Baochan;Shaw, Sarah;Weintraub, Daniel
• 通讯作者: Weintraub, Daniel